Breaking News Instant updates and real-time market news.

SLDB

Solid Biosciences

$31.36

2.095 (7.16%)

, SRPT

Sarepta

$105.48

(0.00%)

10:33
06/19/18
06/19
10:33
06/19/18
10:33

Solid Biosciences rallies 17% to $34.44 following Sarepta gene therapy data

SLDB

Solid Biosciences

$31.36

2.095 (7.16%)

SRPT

Sarepta

$105.48

(0.00%)

  • 20

    Jun

SLDB Solid Biosciences
$31.36

2.095 (7.16%)

04/02/18
LEER
04/02/18
NO CHANGE
Target $14
LEER
Outperform
Solid Biosciences price target lowered to $14 from $36 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Solid Biosciences to $14 from $36 saying that while it was able to withstand several initial concerns that were addressed when the company was going public - including preclinical safety, a board member resignation, manufacturing issues -, Solid Biosciences' recent clinical hold announcement was "the straw that broke the camel's back" resulting in a massive selloff. The analyst reiterates an Outperform rating on the shares.
05/10/18
LEER
05/10/18
NO CHANGE
Target $28
LEER
Outperform
Solid Biosciences price target raised to $28 from $14 at Leerink
Leerink analyst Joseph Schwartz raised his price target on Solid Biosciences to $28 from $14 after he updated his model to reflect Q1 results and increased his probability of success estimate for SGT-001 to 30% from 20%. His probability of success estimate for SB-001 is unchanged at 20%, he noted. Schwartz keeps an Outperform rating on Solid Biosciences shares.
05/15/18
LEER
05/15/18
NO CHANGE
Target $121
LEER
Outperform
Sarepta price target raised to $121 from $88 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Sarepta (SRPT) to $121 from $88, while reiterating an Outperform rating on the shares. The analyst notes that Sarepta is one of three companies developing microdystrophin gene therapy for Duchenne muscular dystrophy, in competition with Pfizer (PFE) who acquired Bamboo, and Solid Biosciences (SLDB). With Solid's clinical hold still in place, Sarepta could potentially be first-to-market, and is expected to report the first clinical data for a micro-dystrophin candidate at their R&D day on June 19, he adds.
06/15/18
JPMS
06/15/18
NO CHANGE
JPMS
Overweight
JPMorgan sees favorable setup for Sarepta into Tuesday's event
JPMorgan analyst Anupam Rama sees a favorable setup for shares of Sarepta Therapeutics(SRPT) into the company's R&D day on Tuesday, June 19. His scenario analysis points to a "very favorable" reward/risk profile of 20%-50% upside versus 10%-25% downside. If the gene therapy data meets or beats expectations, Sarepta will clearly be in the pole position in the micro-dystrophin space, Rama tells investors in a research note. The analyst adds that if the Sarepta micro-dystrophin data are viewed positively next week, a clear bar will have been set that Solid Biosciences (SLDB) will need to meet or beat. Rama continues to see risk to Solid shares ahead of next week's readout from Sarepta. He has an Overweight rating on Sarepta with an $87 price target and Underweight rating on Solid Biosciences with a $10 price target.
SRPT Sarepta
$105.48

(0.00%)

06/05/18
NOMU
06/05/18
NO CHANGE
Target $131
NOMU
Buy
Nomura Instinet positive on Dr. Rodino-Klapac joining Sarepta
Nomura Instinet analyst Christopher Marai views the appointment of Dr. Rodino-Klapac as Sarepta Therapeutics' Vice President of a newly created gene-therapy unit positively. The news further indicates that Sarepta is broadly expanding its gene therapy program in neuromuscular diseases, Marai tells investors in a research note. He reiterates a Buy rating on the shares with a $131 price target.
06/15/18
BTIG
06/15/18
INITIATION
Target $120
BTIG
Buy
Sarepta initiated with a Buy at BTIG
BTIG analyst Timothy Chiang started Sarepta Therapeutics with a Buy rating and $120 price target. The company is the leader in the Duchenne muscular dystrophy space with its Exondys 51 estimated to generate sales of $300M in 2018, and its "extensive pipeline" of RNA-splicing product candidates, Chiang tells investors in a research note. While the stock is up 78% year-to-date, there is the potential for further upside as investors get additional visibility on Sarepta's gene therapy and phosphorodiamidate morpholino oligomer programs, the analyst contends.
06/15/18
06/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PetMed Express (PETS) initiated with a Neutral at CL King. 2. Cloudera (CLDR) initiated with a Reduce at Nomura Instinet. 3. Sarepta (SRPT) initiated with a Buy at BTIG. 4. Delphi Technologies (DLPH) initiated with a Perform at Oppenheimer. 5. Enerplus (ERF) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

HLT

Hilton

$70.17

-0.49 (-0.69%)

16:47
10/22/18
10/22
16:47
10/22/18
16:47
Initiation
Hilton initiated  »

Hilton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

SENS

Senseonics

$3.47

-0.14 (-3.88%)

16:46
10/22/18
10/22
16:46
10/22/18
16:46
Hot Stocks
Senseonics announces Aetna's positive coverage decision for Eversense »

Senseonics Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

16:44
10/22/18
10/22
16:44
10/22/18
16:44
Hot Stocks
Chembio Diagnostics acquires opTricon GmbH for $5.5M in cash »

Chembioannounced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

HLT

Hilton

$70.17

-0.49 (-0.69%)

16:43
10/22/18
10/22
16:43
10/22/18
16:43
Initiation
Hilton initiated  »

Hilton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

H

Hyatt

$69.50

-0.18 (-0.26%)

16:43
10/22/18
10/22
16:43
10/22/18
16:43
Initiation
Hyatt initiated  »

Hyatt initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

MAR

Marriott

$111.49

-0.58 (-0.52%)

16:42
10/22/18
10/22
16:42
10/22/18
16:42
Initiation
Marriott initiated  »

Marriott initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

16:41
10/22/18
10/22
16:41
10/22/18
16:41
Earnings
Chembio Diagnostics sees Q3 revenue $9.2M-$9.5M, two estimate consensus $8.05M »

Chembio Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CIEN

Ciena

$30.97

0.23 (0.75%)

16:41
10/22/18
10/22
16:41
10/22/18
16:41
Initiation
Ciena initiated  »

Ciena resumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSTM

HealthStream

$28.30

0.39 (1.40%)

16:40
10/22/18
10/22
16:40
10/22/18
16:40
Earnings
HealthStream sees FY18 revenue growth of 6%-8%, consensus $229.26M »

"Consistent with our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HSTM

HealthStream

$28.30

0.39 (1.40%)

16:38
10/22/18
10/22
16:38
10/22/18
16:38
Hot Stocks
HealthStream CFO Gerard Hayden, Jr. resigns, Scott Roberts named interim CFO »

HealthStream's CFO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

AFMD

Affimed N.V.

$3.15

-0.06 (-1.87%)

16:38
10/22/18
10/22
16:38
10/22/18
16:38
Syndicate
Breaking Syndicate news story on Affimed N.V. »

Affimed N.V. files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMD

ResMed

$102.58

-0.48 (-0.47%)

16:37
10/22/18
10/22
16:37
10/22/18
16:37
Hot Stocks
ResMed says it won German patent infringement case against Fisher & Paykel »

ResMed announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

FN

Fabrinet

$44.71

-0.3 (-0.67%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Initiation
Fabrinet initiated  »

Fabrinet resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$186.64

0.47 (0.25%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Hot Stocks
Wex signs agreement to acquire Noventis »

WEX announced the signing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 26

    Nov

GOOG

Alphabet

$1,100.52

4.11 (0.37%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Hot Stocks
Google's YouTube investing $20M in education resources for 'EduTubers' »

YouTube is investing $20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

HSTM

HealthStream

$28.30

0.39 (1.40%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Earnings
HealthStream reports Q3 EPS 9c, consensus 8c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WASH

Washington Trust

$52.03

-1.25 (-2.35%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Earnings
Washington Trust reports Q3 EPS $1.01, consensus 98c »

"Washington…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FNSR

Finisar

$17.61

-0.19 (-1.07%)

16:34
10/22/18
10/22
16:34
10/22/18
16:34
Initiation
Finisar initiated  »

Finisar resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$45.76

-1.44 (-3.05%)

16:33
10/22/18
10/22
16:33
10/22/18
16:33
Earnings
Enterprise Financial reports Q3 core EPS 86c, consensus 89c »

Reports Q3 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$62.38

-0.7 (-1.11%)

16:33
10/22/18
10/22
16:33
10/22/18
16:33
Hot Stocks
Hexcel backs FY18 free cash flow greater than $230M »

Backs FY18 accrual basis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HXL

Hexcel

$62.38

-0.7 (-1.11%)

16:32
10/22/18
10/22
16:32
10/22/18
16:32
Earnings
Hexcel narrows FY18 adjusted EPS view to $2.99-$3.07 from 2.96-$3.10 »

FY18 consensus $3.03.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

KEYS

Keysight Technologies

$61.96

0.21 (0.34%)

16:32
10/22/18
10/22
16:32
10/22/18
16:32
Initiation
Keysight Technologies initiated  »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOS

BioScrip

$2.93

(0.00%)

16:31
10/22/18
10/22
16:31
10/22/18
16:31
Hot Stocks
BioScrip names John McMahon CAO »

BioScrip announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

LITE

Lumentum

16:31
10/22/18
10/22
16:31
10/22/18
16:31
Initiation
Lumentum initiated  »

Lumentum resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

INFN

Infinera

$6.06

-0.105 (-1.70%)

16:31
10/22/18
10/22
16:31
10/22/18
16:31
Initiation
Infinera initiated  »

Infinera resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.